Thalassaemia gene therapy - Crucell
Latest Information Update: 24 Jun 1998
At a glance
- Originator Crucell
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thalassaemia
Most Recent Events
- 24 Jun 1998 Discontinued-Preclinical for Thalassaemia in Netherlands (Injection)
- 17 Nov 1997 New profile
- 17 Nov 1997 Preclinical development for Thalassaemia in Netherlands (Injection)